Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations. Zepbound sales reached $1.9 billion in ...

Zepbound sales keep soaring, even as weight loss drug growth slows An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. - Image ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Sales of weight-loss drug Zepbound and diabetes drug Mounjaro rose in the fourth quarter. Revenue from Zepbound leapt to $1.91 billion, up from $175.8 million a year earlier. Mounjaro's revenue ...

Her doctor prescribed the cheaper, generic version of the weight-loss drug after her insurer refused to cover Zepbound, the brand-name version made by Eli Lilly. DeBenedetto, now 43, tells me she's ...

Doctors warn about their physical side effects, but they can also have unexpected effects on intimacy. Jeanne and Javier, who have been married for 15 years.Credit...Katherine Wolkoff for The New ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.

Revenue from Zepbound leapt to $1.91 billion, up from $175.8 Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish ...